According to the latest report published by Data Bridge Market Research, the  Cancer Gene Therapy Market

Global cancer gene therapy market size was valued at USD 2.28 billion in 2024 and is projected to reach USD 4.79 billion by 2032, with a CAGR of 9.70% during the forecast period of 2025 to 2032.

DBMR team is focused on understanding client’s business and their needs so that the finest Cancer Gene Therapy Market research report is delivered to the client for a potential growth and success. All the parameters are systematically studied by the experts for offering the best solution to the clients. Request an analyst call or drop down an enquiry to get detailed market report. The report is very helpful for both established business and emerging market player in the industry as it provides profound market insights. The Cancer Gene Therapy Market document endows with the plentiful insights and business solutions that will help attain the new horizons of success.

Stay informed with our latest keyword market research covering strategies, innovations, and forecasts. Download full report: https://www.databridgemarketresearch.com/reports/global-cancer-gene-therapy-market

Cancer Gene Therapy Market Segmentation and Market Companies

Segments

- By Therapy:
- Gene Induced Immunotherapy
- Oncolytic Virotherapy
- Gene Transfer
- By Indication:
- Breast Cancer
- Prostate Cancer
- Melanoma
- Lymphoma
- Others
- By End-Users:
- Hospitals
- Homecare
- Specialty Clinics
- Others

Gene therapy for cancer has been a promising area of research with the potential to revolutionize the treatment landscape. The market can be segmented by therapy into gene-induced immunotherapy, oncolytic virotherapy, and gene transfer. Gene-induced immunotherapy holds a significant market share as it utilizes genetic material to boost the immune system's ability to target and destroy cancer cells. Oncolytic virotherapy involves using viruses to selectively infect and destroy cancer cells. Gene transfer aims to replace or repair faulty genes associated with cancer. By indication, the market is segmented into breast cancer, prostate cancer, melanoma, lymphoma, and others. Breast cancer and prostate cancer segments are anticipated to witness substantial growth due to the rising prevalence of these cancers globally. The market is further segmented by end-users into hospitals, homecare, specialty clinics, and others. Hospitals are expected to dominate this segment due to the availability of advanced infrastructure and skilled healthcare professionals.

Market Players

- Amgen Inc.
- bluebird bio, Inc.
- Celgene Corporation
- Adaptimmune
- Shanghai Sunway Biotech
- GlaxoSmithKline plc
- bluebird bio, Inc.
- Gradalis
- Gilead Sciences, Inc.
- Merck KGaA
- Novartis AG

Key players in the global cancer gene therapy market are actively involved in research and development activities to introduce innovative therapies and gain a competitive edge. Companies such as Amgen Inc., bluebird bio, Inc., and Celgene Corporation are at the forefront of developing gene therapy solutions for cancer treatment. Collaborations, partnerships, and mergers are common strategies adopted by market players to expand their product portfolio and geographical presence. Rising investments in gene therapy research and increasing partnerships between biopharmaceutical companies and research institutions are expected to drive market growth. The market players are focused on obtaining regulatory approvals for their gene therapy products and commercializing them to address the unmet needs of cancer patients globally.

The global cancer gene therapy market is poised for significant growth driven by advancements in therapeutic technologies and increasing investments in R&D activities. Gene therapy has emerged as a promising approach in cancer treatment, offering personalized and targeted solutions for patients. Gene-induced immunotherapy, oncolytic virotherapy, and gene transfer are key segments shaping the market landscape. Gene-induced immunotherapy, in particular, holds immense potential by harnessing the body's immune system to combat cancer cells effectively. Oncolytic virotherapy, on the other hand, utilizes engineered viruses to selectively target and destroy cancer cells, showing promise in enhancing treatment outcomes. Gene transfer, focusing on correcting genetic aberrations associated with cancer, represents a novel strategy in cancer therapy.

In terms of indication, the market segmentation into breast cancer, prostate cancer, melanoma, lymphoma, and other cancer types reflects the diverse therapeutic applications of gene therapy. Breast and prostate cancer segments are anticipated to witness substantial growth, driven by the increasing prevalence of these malignancies worldwide. The demand for innovative treatment options and personalized therapies is expected to fuel the adoption of gene therapy in these indications. Furthermore, the market is segmented by end-users, with hospitals, homecare settings, specialty clinics, and other healthcare facilities playing a crucial role in delivering gene therapy treatments to patients. Hospitals are expected to dominate the market due to their advanced infrastructure and expertise in managing complex oncology cases.

Key market players such as Amgen Inc., bluebird bio, Inc., Celgene Corporation, and others are leading the charge in developing cutting-edge gene therapy solutions for cancer. These companies are heavily investing in research and collaborations to expand their product pipelines and strengthen their market presence. Regulatory approvals and commercialization strategies are key focus areas for market players as they strive to bring innovative gene therapy products to market and address the unmet medical needs of cancer patients globally. The increasing partnerships between biopharmaceutical companies and research institutions underscore the collaborative nature of the gene therapy landscape, driving innovation and accelerating the development of novel treatment modalities.

Overall, the global cancer gene therapy market is poised for robust growth, driven by technological advancements, increasing R&D investments, and the rising demand for personalized cancer treatments. The convergence of immunotherapy, virotherapy, and gene transfer approaches is reshaping the oncology landscape, offering new hope for patients battling various cancer types. With continued innovation and strategic collaborations, the market is poised to witness transformative changes in cancer treatment paradigms, ultimately improving patient outcomes and quality of life.The global cancer gene therapy market is undergoing a significant transformation with the advent of advanced therapeutic technologies and increased investment in research and development activities. Gene therapy has emerged as a pivotal approach in cancer treatment, offering tailored and precise solutions for patients. The market segmentation based on therapy includes gene-induced immunotherapy, oncolytic virotherapy, and gene transfer, each playing a crucial role in shaping the treatment landscape for cancer. Gene-induced immunotherapy stands out due to its ability to leverage genetic material to enhance the immune system's capacity to target and eliminate cancer cells. On the other hand, oncolytic virotherapy utilizes viruses to infect and destroy cancer cells selectively, showing promise in improving treatment outcomes. Gene transfer, focusing on rectifying genetic abnormalities associated with cancer, represents a novel avenue in cancer therapy.

Furthermore, the market segmentation by indication into breast cancer, prostate cancer, melanoma, lymphoma, and other cancer types underscores the diverse applications of gene therapy in treating different malignancies. The segments focusing on breast and prostate cancer are expected to witness substantial growth, driven by the escalating prevalence of these cancers globally. The demand for innovative and personalized treatment options is anticipated to fuel the adoption of gene therapy within these indications. The segmentation by end-users, including hospitals, homecare settings, specialty clinics, and other healthcare facilities, plays a pivotal role in the delivery of gene therapy treatments to patients. Hospitals are poised to lead this segment due to their advanced infrastructure and expertise in managing complex oncology cases effectively.

Leading market players such as Amgen Inc., bluebird bio, Inc., Celgene Corporation, and other key stakeholders are spearheading the development of cutting-edge gene therapy solutions for cancer. These companies are heavily investing in research and forging strategic collaborations to expand their product pipelines and reinforce their market presence. Securing regulatory approvals and executing effective commercialization strategies are focal points for market players as they strive to introduce innovative gene therapy products to the market and cater to the unmet medical needs of cancer patients globally. The burgeoning partnerships between biopharmaceutical firms and research institutions underscore the collaborative nature of the gene therapy domain, driving innovation and accelerating the development of novel treatment modalities. In essence, the global cancer gene therapy market is on track for substantial growth, fueled by technological advancements, escalating R&D investments, and the growing demand for personalized cancer treatments. The integration of immunotherapy, virotherapy, and gene transfer methodologies is reshaping the oncology arena, offering renewed hope for individuals grappling with various cancer types. Through sustained innovation and strategic collaborations, the market is poised to witness transformative changes in cancer treatment paradigms, ultimately enhancing patient outcomes and quality of life.

Frequently Asked Questions About This Report

Which product type is expected to witness the fastest growth through 2033?
How is the Cancer Gene Therapy Market segmented by end-use industry?
How is Greenwashing risk managed in the Cancer Gene Therapy Market industry?
How is Brand Perception changing in the Cancer Gene Therapy Market?
What are the trade barriers affecting the Cancer Gene Therapy Market in Region?
What is the role of automation in Cancer Gene Therapy Market production/delivery?
What is the impact of the Right to Repair on Cancer Gene Therapy Market ESG scores?
What are the feedback loops used by Cancer Gene Therapy Market leaders?
How is the rising prevalence of Industry Need driving Cancer Gene Therapy Market demand?
What are the major challenges the Cancer Gene Therapy Market currently faces?
Which application segment generated the most revenue in 2025?

Browse More Reports:

Middle East and Africa Insect Protein Market
Europe Instrument Cluster Market
Middle East and Africa Instrument Cluster Market
North America Instrument Cluster Market
Europe Insulin Delivery Devices Market
Asia-Pacific Internet of Medical Things (IoMT) Market
Europe Internet of Medical Things (IoMT) Market
Middle East and Africa Internet of Medical Things (IoMT) Market
North America Internet of Medical Things (IoMT) Market
Asia-Pacific Internet of Things (IOT) Healthcare Market
Asia-Pacific Interstitial Cystitis Market
Europe Interstitial Cystitis Market
Middle East and Africa Interstitial Cystitis Market
North America Interstitial Cystitis Market
Europe Interventional Cardiology & Peripheral Vascular Devices

Contact Us:
Data Bridge Market Research
US: +1 614 591 3140
UK: +44 845 154 9652
APAC : +653 1251 980
Email:- [email protected]"